• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Audio Journal of Oncology in Advance – November 15th, 2006

  • — 15 Nov, 2006
Daniel Petrylak
Daniel Petrylak
Oliver Sartor
Oliver Sartor
Mark Socinski
Mark Socinski
Kanti Rai
Kanti Rai
Edward Ambinder
Edward Ambinder

Chemo- and Immunotherapy Working Together in Hormone Refractory Prostate Cancer

REFERENCE: Chemotherapy Foundation Symposium XXIV 8-11 November 2006
DANIEL PETRYLAK, Columbia Presbyterian Medical Center, New York
COMMENT: EDWARD AMBINDER, Mount Sinai School of Medicine, New York

In hormone refractory prostate cancer, chemotherapy and immunotherapy can work together – and the next task is to work out how best to combine them. Daniel Petrylak of the Columbia Presbyterian Medical Center in New York had the details.

Satraplatin for Hormone Refractory Prostate Cancer

REFERENCE: Chemotherapy Foundation Symposium XXIV 8-11 November 2006
OLIVER SARTOR, Dana-Farber Cancer Institute, Boston
COMMENT: EDWARD AMBINDER, Mount Sinai School of Medicine, New York

According to Oliver Sartor of the Dana-Farber Cancer Institute in Boston, the platinum agent satraplatin is a possible new treatment for androgen-independent prostate cancer.

Paclitaxel Poliglumex More Effective in Women with Non Small-Cell Lung Cancer?

REFERENCE: Chemotherapy Foundation Symposium XXIV 8-11 November 2006
MARK SOCINSKI, University of North Carolina, Chapel Hill
Paclitaxel linked to a polyglutamate backbone could work better in women – but some new evidence has raised concerns for investigators. Mark Socinski of the University of North Carolina in Chapel Hill shared the data in New York.

Antisense Therapy Shows Promise in Chronic Lymphocytic Leukemia

REFERENCE: Chemotherapy Foundation Symposium XXIV 8-11 November 2006
KANTI RAI, Long Island Jewish Medical Center, New York
COMMENT: EDWARD AMBINDER, Mount Sinai School of Medicine, New York

Kanti Rai of the Long Island Jewish Medical Center in New York has had encouraging results from adding the antisense molecule Genasense to chemotherapy, in patients with relapsed or refractory CLL.


To listen this episode please go to ASCO Audio Journal of Oncology in Advance Presentations.

You may also like...

  • Cabozantinib Improved Hepatocellular Carcinoma Survival Beyond Sorafenib Cabozantinib Improved Hepatocellular Carcinoma Survival Beyond Sorafenib 15 Oct, 2018
  • Hormone Refractory Prostate Cancer: Increased Progression-Free Survival With Satraplatin and Prednisone Hormone Refractory Prostate Cancer: Increased Progression-Free Survival With Satraplatin and Prednisone 1 Feb, 2008
  • Richard Carvajal MEK-inhibitor selumetinib doubles progression free survival in advanced uveal melanoma 13 Jun, 2013
  • Radiotherapy Triggers Durable Immunotherapy Responsiveness Beyond Radiation Field Radiotherapy Triggers Durable Immunotherapy Responsiveness Beyond Radiation Field 24 Aug, 2016
  • Previous story Audio Journal of Cardiovascular Medicine: reporting from American Heart Association Scientific Sessions, Chicago, November 12-15, 2006
  • Next story Audio Journal of Cardiovascular Medicine: reporting from American Heart Association Scientific Sessions, Chicago, November 12-15, 2006
  • News

    • Liquid Biopsy ctDNA Prediction of Lung Cancer Relapse “Ready for Prime Time”Liquid Biopsy ctDNA Prediction of Lung Cancer Relapse “Ready for Prime Time”August 4, 2022
    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
  • Related interviews

    • Ibrutinib: New Frontline Standard for Chronic Lymphocytic…
    • Microbiome Diversity Key To Survival After Allogeneic…
    • New Front Line Standard for Older Patients with Chronic…
    • Genomic-led AML Clinical Decision Making Within Seven Days
    • How Babies Use Object Permanence To Get What They Want
  • Home
  • Oncology
  • ASCO
  • Audio Journal of Oncology in Advance – November 15th, 2006

© Copyright 2022 AudioMedica.com. Typegrid Theme by WPBandit.